started · updated
Chile approves Picmagluti, first chemically synthesized semaglutide
Chile’s Institute of Public Health (ISP) has granted sanitary registrations to Picmagluti, an injectable semaglutide solution developed by Dr. Reddy’s Laboratories Chile. This marks the first time a chemically synthesized version of the active ingredient—commonly known through the brand Ozempic—has been authorized in the country.
The ISP issued two specific registrations: one for 0.25 mg and 0.5 mg doses, and another for the 1 mg presentation. Unlike Ozempic, which is a biological product produced via recombinant technology, Picmagluti is composed of chemically synthesized peptides.
Medical experts note that while the active ingredient is the same, the manufacturing process differs, requiring distinct regulatory evaluations regarding technical safety and efficacy. The ISP is currently reviewing 11 additional applications for synthetic semaglutide from four different laboratories, which could further expand pharmacological alternatives in the Chilean market.
Entities
Chile · Dr. Reddy’s Laboratories Chile · Institute of Public Health · Picmagluti